tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Stephen Unger, 70 are a BUY (90.91%), 6 are a HOLD (7.79%), 1 are a SELL (1.3%).
Analyst Stephen Unger, carries an average stock price target met ratio of 88.86% that have a potential upside of 28.49% achieved within 127 days. Previously, Stephen Unger worked at NEEDHAM.
Stephen Unger’s has documented 133 price targets and ratings displayed on 14 stocks. The coverage was on Healthcare, Technology, Industrials sectors.
Most recent stock forecast was given on NEO, NeoGenomics at 28-Mar-2022.
Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2020. The price target of $4 was fulfilled within 68 days with a profit of $2.26 (129.89%) receiving and performance score of 19.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$40
$4.72 (13.38%)
$46
12 days ago
(02-Oct-2025)
0/6 (0%)
$5.17 (14.84%)
Hold
$40
$4.72 (13.38%)
$48
2 months 9 days ago
(05-Aug-2025)
7/10 (70%)
$7.98 (24.92%)
191
Buy
$50
$14.72 (41.72%)
$60
2 months 9 days ago
(05-Aug-2025)
4/7 (57.14%)
$17.98 (56.15%)
256
Buy
$50
$14.72 (41.72%)
$80
3 months 18 days ago
(26-Jun-2025)
0/3 (0%)
$7.88 (18.71%)
Hold
$45
$9.72 (27.55%)
$66
5 months 6 days ago
(08-May-2025)
13/15 (86.67%)
$4.6 (11.39%)
254
What Year was the first public recommendation made by Stephen Unger?
